HHS, BARDA partner with Hologic to expedite development of a high-throughput, automated multiplex SARS-CoV-2/Flu assay

About Image

BARDA expanded an existing partnership with Hologic, Inc., headquartered in Marlborough, Massachusetts, to accelerate the development of a new Aptima SARS-CoV-2/Flu Assay that can simultaneously detect and differentiate RNA from SARS-CoV-2, Influenza A, and Influenza B in respiratory specimens. Since these viruses present with overlapping clinical symptoms, this single test may be able to determine if a patient with fever and respiratory symptoms has COVID-19 or influenza, which will help guide disease management and patient treatment.

With multiplex assays, only one specimen is collected from each patient, reducing the need for critical supplies such as swabs or personal protective equipment. Combining multiple assays into a single test also helps preserve limited testing reagents.

The Aptima SARS-CoV-2/Flu Assay runs on the Panther system, a fully automated, high-throughput molecular diagnostic platform that is widely used in the U.S., with over 1,100 instruments installed across all 50 states. Each Panther system can provide initial results in less than three hours and process more than 1,000 tests in a 24-hour period.

About Hologic:

The following information is provided by company and does not indicate endorsement by the federal government of the company or its products.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. Learn more at www.hologic.com.

Last Updated: October 29, 2020

COVID-19 Medical Countermeasure Portfolio

This award is one component of BARDA's expanding COVID-19 medical countermeasure portfolio; visit BARDA's COVID-19 Portfolio to learn more.